I agree. A decade of silence hasn’t been fruitful. Though initially, post 2016, to neutralize AF, that silence must have been valid. Now, sitting on the threshold of a major approval, communicating other things about the company and the science, things permissible, should be done. They have got DI and GZ and they might have some other staff as well. PR can and should get fa more active and robust.
I cannot shake the notion that a lower stock price is benefiting more than shorts. If we end up doing a stock swap with Toucan owned future partners then the stock price could be a great benefit to them. I dont understand how a CEO could go year after year after year with making no effort to market the platform to maximize shareholder value which would ease dilution pain. She simply doesn't care... why???????
I don’t think fluff PRs help. You have seen the reaction on leukapheresis clinic announcement and the news of Advent purchase. Ultimately, it all boils down to relentless execution on key strategic initiatives. Three most important ones that markets want to know in conjunction with a UK decision:
1) NICE evidence submission PR 2) Significant non dilutive funding from big pharma 3) FDA BLA submission
Everything else is noise at this point, almost 6 years from data lock. It’s almost like it’s priced in because it was expected after such a long wait, and therefore market is unlikely to react positively.
Hopefully, there will be less frustration for you moving forward once you make peace with some of this!
Market Data 
Markets 
AI
